Supreme Court temporarily lifts telehealth ban on abortion drug mifepristone
May 4 (UPI) -- The Supreme Court on Monday blocked a lower court's ruling that implemented a nationwide ban on doctors prescribing the abortion drug mifepristone during telehealth visits.
The high court temporarily reinstated telehealth and mail access to the drug while it considers the case.
The 5th U.S. Circuit Court of Appeals on Friday unanimously ruled in favor of the state of Louisiana in its case asking for the ban.
One of the manufacturers of the drug, Danco, filed an appeal with the Supreme Court on Saturday asking for the ban to be lifted. The company said the appellate court's ruling leaves patients stuck in limbo because it didn't clarify the legal use of the drug.
About half of all abortions in the United States use medications such as mifepristone.
"Danco has been free to rely on procedures set by the FDA to distribute its product," lawyers for Danco said in a filing with the court.
"The Fifth Circuit's decision immediately ends that," the lawyers said. "A stay should issue to prevent the disruption and confusion that will result if the decision below were to remain operative."
Another maker of mifepristone, GenBioPro, also filed an appeal.
The Supreme Court said the temporary stay would be in place until 5 p.m. EDT May 11.
The Food and Drug Administration approved mifepristone for the medical termination of a pregnancy in 2000. During the COVID-19 pandemic, the FDA temporarily allowed doctors to prescribe the drug during telehealth visits and in 2023 adopted the rule permanently.
Copyright 2026 UPI News Corporation. All Rights Reserved.
This story was originally published May 4, 2026 at 12:26 PM.